Skip to content

Septerna, Inc. SEPN EBITDA margin

EBITDA margin at other companies

Amgen logo
AmgenAMGN
41.5%+3.4pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-572.1%-593pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-427.3%+42.6pp
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-10.2%-3.5pp
Precigen logo
PrecigenPGEN
-2,807.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
51.2%+0.9pp

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.65B+319%
Enterprise value$1.6B+1,325%
P/S22.8×-379×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Calculated from Septerna, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s EBITDA margin?
Septerna, Inc. (SEPN) reported EBITDA margin of -74.8% in Q1 2026.
How has Septerna, Inc.'s EBITDA margin changed year-over-year?
Septerna, Inc.'s EBITDA margin increased by 99.2% year-over-year, from -9,187.4% to -74.8%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.